For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 202,862 | |||
| General and administrative | 41,972 | |||
| Total operating expenses | 244,834 | |||
| Operating loss | -244,834 | |||
| Interest expense | 7,248 | |||
| Other income, net | 22,372 | |||
| Loss before income tax | -229,710 | |||
| Income tax expense | 611 | |||
| Net loss | -230,321 | |||
| Of which net loss attributable to controlling interests shareholders | -227,318 | |||
| Basic EPS | -3.53 | |||
| Diluted EPS | -3.53 | |||
| Basic Average Shares | 64,463,889 | |||
| Diluted Average Shares | 64,463,889 | |||
MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics (MLTX)